Role of pRb/p16/cdk4/cyclin D1 in Melanoma Development
Author Information
Author(s): GM Maelandsmo, VA Florenes, E Hovig, T OYjord, O Engebraaten, R Holm, A-L Borresen, O Fodstad
Primary Institution: Institute for Cancer Research, The Norwegian Radium Hospital
Hypothesis
The study aims to examine the frequency of gene aberrations involving CDKN2, CDK4, and CCND1 in sporadic metastatic melanomas.
Conclusion
The study found that functional inactivation of pRb through the p16/cdk4/cyclin D1 pathway may be involved in the development or progression of sporadic human melanomas.
Supporting Evidence
- Homozygous deletions of CDKN2 were found in 11% of tumors and 40% of melanoma cell lines.
- 59% of metastatic lesions lacked detectable expression of p16 mRNA.
- 76% of tumors showed high levels of CDK4 mRNA.
Takeaway
Researchers looked at skin cancer samples to see how certain genes were changed, and they found that many had problems with a gene that helps control cell growth.
Methodology
Biopsies from 61 patients with sporadic malignant melanoma were analyzed for gene deletions, mutations, and expression levels.
Limitations
The study may underestimate the frequency of CDKN2 deletions due to contamination with normal cells in tumor biopsies.
Participant Demographics
Patients with sporadic malignant melanoma, including various histological subtypes.
Want to read the original?
Access the complete publication on the publisher's website